N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men

International Journal of Urology

Volumn 10, Issue 3, 2003, Pages 167-173

  Hamasaki, Takashi ^a,c   Inatomi, Hisato ^a   Katoh, Takahiko ^b   Aono, Hisami ^a   Ikuyama, Toshihiro ^a   Muratani, Tetsuro ^a   Matsumoto, Tetsuro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Japanese; Metabolic enzyme; N acetyltransferase 2; Prostate cancer; Smoking status

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; BIOLOGICAL MARKER; DRUG METABOLIZING ENZYME; UNCLASSIFIED DRUG;

ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; ASIAN; CANCER GRADING; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING;

ACETYLATION; AGED; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JAPAN; MALE; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037365308     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2003.00586.x     Document Type: Article

References (34)

1. Taylor JD, Holmes TM, Swanson GM. Descriptive epidemiology of prostate cancer in metropolitan Detroit. Cancer 1994; 73: 1704-7.
2. Oishi K, Yoshida O, Schroeder FH. The geography of prostate cancer and its treatment in Japan. Cancer Surv. 1995; 23: 267-80.
3. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Cancer 1992; 70: 2861-9.
4. Rodriguez C, Tatham LM, Thun MJ, Calle EE, Heath C Jr. Smoking and fatal prostate cancer in a large cohort of adult men. Am. J. Epidemiol. 1997; 145: 466-75.
5. Wadelius M, Autrup JL, Stubbins MJ et al. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 1999; 9: 333-40.
6. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann. Intern. Med. 1993; 118: 793-803.
7. Ingles SA, Ross RK, Yu MC et al. Association of prostate cancer risk with genetic polymorphisms in the vitamin D receptor and androgen receptor. J. Natl Cancer Inst. 1997; 89: 166-70.
8. Habuchi T, Suzuki T, Sasaki R et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000; 60: 305-8.
9. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T. Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr. J. 2001; 48: 543-9.
10. Caporaso N, Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics 1995; 5: 59-63.
11. Murata M, Watanabe M, Yamanaka M et al. Genetic polymorphisms in cytochrome P 450 (CYP) 1A1, CYP 1A2, CYP 2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett. 2001; 165: 171-7.
12. Kote-Jarai Z, Easton D, Edwards SM et al. Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics 2001; 11: 325-30.
13. Guengerich FP. Influence of nutrients and other dietary materials on cytocrome P-450 enzymes. Am. J. Clin. Nutr. 1995; 61: 651-8.
14. Katoh T, Inatomi H, Yang M, Kawamoto T, Matsumoto T, Bell DA. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese. Pharmacogenetics 1999; 9: 401-4.
15. Inatomi H, Katoh K, Kawamoto T, Matsumoto T. NAT 2 gene polymorphism as a possible biomarker for susceptibility to bladder cancer in Japanese. Int. J. Urol. 1999; 6: 446-54.
16. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 1998; 19: 1803-7.
17. Chen J, Stampfer MJ, Hough HL et al. A prostective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res. 1998; 58: 3307-11.
18. Grant DM, Hughes NC, Janezic SA et al. Human acetyltransferase polymorphisms. Mutat. Res. 1997; 276: 61-70.
19. Grant DM, Hughes NC, Janezic SA, Sampson H, Darlington G, Jeweet MA. Interindividual variation in cytochrome P4501A1, acetyltransferase NAT1 and NAT2 and risk of bladder cancer: a case control study. Proc. Am. Assoc. Cancer Res. 1998; 39: 455.
20. Evans DP. N-Acetylyransferase. Pharmacol. Ther. 1989; 42: 157-234.
21. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl Acad. Sci. USA 1991; 88: 5237-41.
22. Bell DA, Taylor JA, Butler MA et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14: 1689-92.
23. Hickman D, Risch A, Camilleri J, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: Identification of slow allotypic variants. Phamacogenetics 1992; 2: 217-26.
24. Japanese Urological Association and the Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Prostate Cancer, 3rd edn. Kanehara Publications. Co, Tokyo, 2001.
25. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotype and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem. 1990; 267: 18140-7.
26. Ross RK, Henderson BE. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J. Natl Cancer Inst. 1994; 86: 252-4.
27. Kolonel LN. Nutrition and prostate cancer. Cancer Causes Control 1996; 7: 83-94.
28. Nagao M, Shigemura T. Carcinogenetic factors in food with relevance to colon cancer development. Mutat. Res. 1993; 290: 43-51.
29. Shirai T, Sano M, Tamano S et al. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhlP) derived from cooked foods. Cancer Res. 1997; 57: 195-8.
30. Leff MA, Epstein PN, Doll MA et al. Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J. Pharmacol. Exp. Ther. 1999; 290: 182-7.
31. Wang CY, Debice-Rychter M, Schut HA et al. N-acetyltransferase expression and DNA binding N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis 1999; 20: 1501-5.
32. Delemenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. Genotyping of polymorphic N-acetyltransferase (NAT2) gene locus in two native African populations. Pharmacogenetics 1996; 6: 177-85.
33. Henry JL, Chun-Ya H, Bruce KL, Steven H. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharamacogenetics 1994; 4: 125-34.
34. Rebbeck TR, Walker AH, Jaffe JM, White DL, Wein AJ, Malkowicz SB. Glutathione S-transferase-μ (GSTM1) and θ (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 1999; 8: 283-7.